TUMAINI: Vaccine Candidates Against Bundibugyo Virus Disease (BVD) in Contacts of Cases

Phase 3, randomised, double-blind trial in Bundibugyo virus disease (BVD) (2 arms). Primary endpoints: Proportion of participants experiencing serious adverse events, suspected unexpected serious adverse reactions, adverse events of special interest, or medically attended adverse events at Day 181, Vaccine efficacy against polymerase chain reaction (PCR)-confirmed symptomatic Bundibugyo virus disease and 1 more. Planned start Oct 2026; status: not yet recruiting.